Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Given Imaging results

This article was originally published in The Gray Sheet

Executive Summary

Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts